SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

OXLUMO

ALNY·ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercialized, FDA approval catalyst recorded 2020-11-23; it has been on the market for years.
Why 3/10
No hard, dated catalyst for OXLUMO is scheduled in the next ~12 months, its FDA approval already passed years ago, it is a marketed product with no pending regulatory decision, and it is a small slice of Alnylam's revenue, so it lands at 3 on the impact scale.
Actionable Insight NEUTRAL

OXLUMO itself is not a near-term stock driver, do not trade ALNY on it. Watch Alnylam's quarterly earnings for OXLUMO's contribution and the pipeline catalysts that actually move the stock: the cemdisiran NDA (submitted to FDA 2026-04-30 for generalized myasthenia gravis) and zilebesiran/nucresiran readouts; ALNY is currently deeply oversold (RSI ~23.5) after a Q2 2026 EPS/revenue miss and full-year TTR guidance cut.

Price Chart

Loading chart...

Executive Summary

OXLUMO is the brand name for lumasiran, Alnylam Pharmaceuticals' FDA-approved RNAi treatment for primary hyperoxaluria type 1, an ultra-rare genetic kidney-stone disease. SecBot records confirm an OXLUMO FDA approval catalyst for ALNY dated 2020-11-23, and Alnylam's Q2 2026 earnings analysis lists OXLUMO as one of its four marketed products, but it is a small, niche contributor next to the TTR franchise (AMVUTTRA alone was ~$1.012B of $1.172B net product revenue in Q2 2026).

How It Works

OXLUMO (lumasiran) is an RNA-interference (RNAi) medicine given by under-the-skin injection that silences a liver gene (HAO1) responsible for generating oxalate, the substance that forms kidney stones. In patients with primary hyperoxaluria type 1, an ultra-rare inherited disease, this cuts oxalate production and lowers the risk of recurrent kidney stones and progressive kidney damage.

Trial Status

Marketed product: SecBot's catalyst/outcome records show an FDA approval for OXLUMO dated 2020-11-23 (stock +0.77% 1-day, +4.14% 5-day around that approval). Alnylam's Q2 2026 earnings filing analysis lists OXLUMO among the company's commercial drugs (with AMVUTTRA, ONPATTRO, GIVLAARI). No open Phase 2/3 lumasiran trials appeared in SecBot's ClinicalTrials.gov-ingested pipeline records.

The Two-Sided Case

▲ Bull Case3
Approved and on the market: SecBot catalyst records show an FDA approval for OXLUMO (ALNY) on 2020-11-23, and the Q2 2026 earnings filing analysis lists OXLUMO among Alnylam's four commercial products, it generates revenue with no remaining regulatory binary risk.
Wall Street is broadly positive on the owner: ALNY analyst consensus is 29 Buy/Strong-Buy vs 9 Hold and 0 Sell, with a mean price target of $427.61 versus the $205.52 price, roughly 106.8% implied upside per ticker_overview (2026-07-31).
The stock's reaction to the OXLUMO approval catalyst itself was positive but calm (+0.77% 1-day, +4.14% 5-day), typical of a niche product approval, no binary overhang left.
▼ Bear Case5
No hard, dated catalyst for OXLUMO in the next ~12 months: it has been approved since Nov 2020, and the drugs that actually move ALNY now are the TTR franchise and pipeline (cemdisiran NDA 2026-04-30; zilebesiran, nucresiran, mivelsiran), OXLUMO is a minor part of the story.
Company-level tape is bearish: ALNY reported Q2 2026 non-GAAP EPS $1.84 vs $2.15 consensus (-14.4%) and revenue $1.291B vs $1.32B (-2.2%), and cut full-year TTR net product revenue guidance from $4.4B-$4.7B to $4.2B-$4.5B (local analysis of the 2026-07-30 8-K).
Technical/quant picture is weak: ALNY at $205.52 sits ~41% below its 200-day SMA ($349.29), RSI 23.5 (oversold), MACD bearish cross, and quant composite -59 (7/31/2026 snapshot); short interest ~4.32% of estimated shares outstanding with ~3.24 days-to-cover as of the 7/15/2026 settlement.
OXLUMO's addressable patient population (primary hyperoxaluria type 1) is ultra-rare, capping its commercial ceiling relative to the rest of Alnylam's portfolio.
External web verification was unavailable this session, so indication/mechanism and revenue details could not be independently re-confirmed beyond SecBot's internal records, treat unverified specifics with extra caution.

Upcoming Catalysts

  • None scheduled for OXLUMO itself.
  • Company-level catalysts that move ALNY instead: cemdisiran NDA (submitted 2026-04-30 for generalized myasthenia gravis) and pipeline readouts for zilebesiran, nucresiran and mivelsiran.
  • Quarterly earnings (Q2 2026 reported 2026-07-30; guidance cut bears watching) for OXLUMO's contribution to the product revenue mix.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov